HomeNewsHealth & FitnessWHO to consider emergency use listing of Covaxin at today's meeting: Health Minister Mansukh Mandaviya

WHO to consider emergency use listing of Covaxin at today's meeting: Health Minister Mansukh Mandaviya

The global health body's technical advisory group is meeting to consider the emergency use listing of the vaccine.

October 26, 2021 / 14:35 IST
Story continues below Advertisement
Union Health Minister Mansukh Mandaviya
Union Health Minister Mansukh Mandaviya

The World Health Organization (WHO) will meet on October 26 to consider much-coveted emergency use approval to Covaxin, India's indigenously made vaccine against COVID-19, Union Health Minister Mansukh Mandaviya said.

The global health body's technical advisory group is meeting to consider the emergency use listing (EUL) of the vaccine, the minister said.

Story continues below Advertisement

“WHO has a system in which there is a technical committee which has approved it (Covaxin) while the other committee is meeting today. The approval for Covaxin will be given on the basis of today's meeting,” Mandaviya told reporters in Delhi.

READ: Health Minister Mansukh Mandaviya says government panel looking into new Delta subvariant

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show